Current Therapies in Clinical Trials of Parkinson’s Disease: A 2021 Update
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current Therapies in Clinical Trials of Parkinson’s Disease: A 2021 Update
Authors
Keywords
-
Journal
Pharmaceuticals
Volume 14, Issue 8, Pages 717
Publisher
MDPI AG
Online
2021-07-26
DOI
10.3390/ph14080717
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture
- (2021) Ruth Chia et al. NATURE GENETICS
- α-synuclein aggregates induce c-Abl activation and dopaminergic neuronal loss by a feed-forward redox stress mechanism
- (2021) Soumitra Ghosh et al. PROGRESS IN NEUROBIOLOGY
- The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review
- (2021) Angelo Antonini et al. ADVANCES IN THERAPY
- Targeting the cholinergic system in Parkinson’s disease
- (2020) Changliang Liu ACTA PHARMACOLOGICA SINICA
- NYX‐458 improves cognitive performance in a primate Parkinson's disease model
- (2020) A.L Barth et al. MOVEMENT DISORDERS
- Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations
- (2020) Stephen Mullin et al. JAMA Neurology
- Clinical Trial Highlights – GLP-1 agonists
- (2020) Kevin McFarthing et al. Journal of Parkinsons Disease
- Safety of Plasma Infusions in Parkinson's Disease
- (2020) Jordan E. Parker et al. MOVEMENT DISORDERS
- The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson’s Disease: A Feasibility Study
- (2020) Xuemei Huang et al. Journal of Parkinsons Disease
- Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson’s Disease
- (2020) E. Maruthi Prasad et al. Antioxidants
- Minocycline reduces inflammatory response and cell death in a S100B retina degeneration model
- (2020) Pia Grotegut et al. Journal of Neuroinflammation
- The Future of GDNF in Parkinson's Disease
- (2020) Fredric P. Manfredsson et al. Frontiers in Aging Neuroscience
- Clinical Trial Highlights: Targetting Alpha-Synuclein
- (2019) Kevin McFarthing et al. Journal of Parkinsons Disease
- Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease
- (2019) Constant V.M. Verschuur et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
- (2019) Eloise Hudry et al. NEURON
- Deep brain stimulation: current challenges and future directions
- (2019) Andres M. Lozano et al. Nature Reviews Neurology
- Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial
- (2019) C. R. A. Silveira et al. BMC Neurology
- The current status of pharmacotherapy for the treatment of Parkinson’s disease: transition from single-target to multitarget therapy
- (2019) Siew L. Cheong et al. DRUG DISCOVERY TODAY
- Gene Therapy Leaves a Vicious Cycle
- (2019) Reena Goswami et al. Frontiers in Oncology
- The impact of levodopa therapy-induced complications on quality of life in Parkinson’s disease patients in Singapore
- (2019) Jonathan Wu et al. Scientific Reports
- Improving the odds of drug development success through human genomics: modelling study
- (2019) Aroon D. Hingorani et al. Scientific Reports
- Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease
- (2019) Carroll Rutherford Fields et al. Frontiers in Molecular Neuroscience
- Celastrol Inhibits Dopaminergic Neuronal Death of Parkinson’s Disease through Activating Mitophagy
- (2019) Ming-Wei Lin et al. Antioxidants
- A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson’s Disease
- (2018) Rachel Gurrell et al. CLINICAL DRUG INVESTIGATION
- Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN
- (2018) Christian Hinderer et al. HUMAN GENE THERAPY
- Gene Therapy for Parkinson’s Disease, An Update
- (2018) Tobias M. Axelsen et al. Journal of Parkinsons Disease
- Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease
- (2018) Joseph Jankovic et al. JAMA Neurology
- Adverse Effects of Immunoglobulin Therapy
- (2018) Yi Guo et al. Frontiers in Immunology
- Adenosine A2A Receptor Antagonists in Neurodegenerative Diseases: Huge Potential and Huge Challenges
- (2018) Rafael Franco et al. Frontiers in Psychiatry
- Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons
- (2018) J. Magalhaes et al. Scientific Reports
- A phase IIb, randomised, double-blind, placebo-controlled, dose-ranging investigation of the safety and efficacy of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease
- (2018) Barry Snow et al. PARKINSONISM & RELATED DISORDERS
- A Proposed Roadmap for Parkinson’s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein
- (2018) Kalpana M. Merchant et al. Journal of Parkinsons Disease
- The Emerging Evidence of the Parkinson Pandemic
- (2018) E. Ray Dorsey et al. Journal of Parkinsons Disease
- Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models
- (2018) Andreas Weihofen et al. NEUROBIOLOGY OF DISEASE
- High-dose transdermal nicotine in Parkinson's disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study
- (2017) G. Villafane et al. EUROPEAN JOURNAL OF NEUROLOGY
- Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease
- (2017) Andrew B. West EXPERIMENTAL NEUROLOGY
- NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory
- (2017) M Amin Khan et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Caffeine as symptomatic treatment for Parkinson disease (Café-PD)
- (2017) Ronald B. Postuma et al. NEUROLOGY
- Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy
- (2017) Ádám Annus et al. Drug Design Development and Therapy
- Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease
- (2016) Jie Dong et al. Current Neuropharmacology
- G protein-coupled receptor kinases as regulators of dopamine receptor functions
- (2016) Eugenia V. Gurevich et al. PHARMACOLOGICAL RESEARCH
- Gene Therapy: A Promising Approach for Neuroprotection in Parkinson’s Disease?
- (2016) Pamela Valdés et al. Frontiers in Neuroanatomy
- Economic Analysis of Deep Brain Stimulation in Parkinson Disease: Systematic Review of the Literature
- (2016) Jaime Eduardo Becerra et al. World Neurosurgery
- Blood Plasma of Patients with Parkinson’s Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity
- (2016) Peng Wang et al. Parkinsons Disease
- Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies
- (2015) Sabeena Sharma et al. BIOMEDICINE & PHARMACOTHERAPY
- Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease
- (2015) Aurelija Jucaite et al. BRAIN
- Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson’s disease
- (2015) Changyoun Kim et al. Journal of Neuroinflammation
- Effect of Sarizotan, a 5-HT1aand D2-Like Receptor Agonist, on Respiration in Three Mouse Models of Rett Syndrome
- (2014) Ana P. Abdala et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Deep Brain Stimulation for Obsessive-Compulsive Disorder
- (2014) Clement Hamani et al. NEUROSURGERY
- Protective effect of WIN-1001X, an herbal extract, on Parkinson's disease experimental model via autophagy enhancement
- (2014) J Kim et al. PLANTA MEDICA
- Measuring Disease Progression in Early Parkinson Disease
- (2014) Sotirios A. Parashos et al. JAMA Neurology
- N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease
- (2013) David Olivares et al. Current Alzheimer Research
- Kinase Inhibitors: Adverse Effects Related to the Endocrine System
- (2013) Maya B. Lodish JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
- (2013) R. T. Bartus et al. NEUROLOGY
- Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease
- (2013) Amaal AlDakheel et al. Neurotherapeutics
- -Synuclein in Parkinson's Disease
- (2013) L. Stefanis Cold Spring Harbor Perspectives in Medicine
- Parkinson's Disease: Gene Therapies
- (2013) P. G. Coune et al. Cold Spring Harbor Perspectives in Medicine
- Clinical application of stem cell therapy in Parkinson's disease
- (2012) Marios Politis et al. BMC Medicine
- The Role of Free Radicals in the Aging Brain and Parkinson’s Disease: Convergence and Parallelism
- (2012) Hemant Kumar et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The hypoxia imaging agent Cu II (atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease
- (2012) Lin W. Hung et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Randomized trial of deep brain stimulation for Parkinson disease: Thirty-six-month outcomes
- (2012) F. M. Weaver et al. NEUROLOGY
- Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia
- (2012) Veronica Ghiglieri et al. Parkinsons Disease
- Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial
- (2011) Robert E Gross et al. LANCET NEUROLOGY
- The Physiology, Signaling, and Pharmacology of Dopamine Receptors
- (2011) J.-M. Beaulieu et al. PHARMACOLOGICAL REVIEWS
- The Use of Solvent/Detergent Treatment in Pathogen Reduction of Plasma
- (2011) Peter Hellstern et al. TRANSFUSION MEDICINE AND HEMOTHERAPY
- Update on the use of pramipexole in the treatment of Parkinson’s disease
- (2011) Radu Constantinescu Neuropsychiatric Disease and Treatment
- The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa
- (2010) S. Kaakkola et al. ACTA NEUROLOGICA SCANDINAVICA
- Future of cell and gene therapies for Parkinson's disease
- (2010) Ole Isacson et al. ANNALS OF NEUROLOGY
- Emerging Opportunities and Concerns for Drug Discovery at Serotonin 5-5-HT2B Receptors
- (2010) Jose Brea et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats
- (2010) Yoshihiro Tani et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative
- (2010) Vanessa Villard et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
- (2010) William J Marks et al. LANCET NEUROLOGY
- Levodopa: the story so far
- (2010) Alison Abbott NATURE
- Pallidal versus Subthalamic Deep-Brain Stimulation for Parkinson's Disease
- (2010) Kenneth A. Follett et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacology of signaling induced by dopamine D1-like receptor activation
- (2010) Ashiwel S. Undieh PHARMACOLOGY & THERAPEUTICS
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- (2009) Jorg Hartmann et al. CURRENT DRUG METABOLISM
- Dopamine Cell Implantation in Parkinson's Disease: Long-Term Clinical and 18F-FDOPA PET Outcomes
- (2009) Y. Ma et al. JOURNAL OF NUCLEAR MEDICINE
- Role of dopamine receptor agonists in the treatment of early Parkinson's disease
- (2009) Ubaldo Bonuccelli et al. PARKINSONISM & RELATED DISORDERS
- Selective serotonin reuptake inhibitors pathway
- (2009) Katrin Sangkuhl et al. Pharmacogenetics and Genomics
- Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion
- (2009) Steven H. Kleinman et al. TRANSFUSION
- Tesofensine (NS 2330), a Monoamine Reuptake Inhibitor, in Patients With Advanced Parkinson Disease and Motor Fluctuations
- (2008) Olivier Rascol ARCHIVES OF NEUROLOGY
- Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease
- (2008) Michael A. Schwarzschild ARCHIVES OF NEUROLOGY
- Pathogen safety of plasma-derived products - Haemate®P/Humate-P®
- (2008) A. GRÖNER HAEMOPHILIA
- Placebo influences on dyskinesia in Parkinson's disease
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
- α-Synuclein: A therapeutic target for Parkinson’s disease?
- (2008) K MAGUIREZEISS PHARMACOLOGICAL RESEARCH
- Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease
- (2007) Doron Merims et al. PARKINSONISM & RELATED DISORDERS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now